What Cellular Intelligence does

Cellular Intelligence (legal entity: Somite Therapeutics, Inc.) is a Boston-based AI-native TechBio company building what it describes as the first universal virtual cell-signaling foundation model — a transformer-based architecture trained to predict how any human cell, in any state, will respond to external biological signals. The company was founded in 2023 as Somite by repeat AI entrepreneur Micha Breakstone (previously sold Chorus.ai for $575M), MIT's Jonathan Rosenfeld, and four scientific co-founders from Harvard Medical School and the University of Washington. Its core technology stack comprises a proprietary capsule-based split-and-pool data generation platform that produces context-rich perturbation data at roughly 1,000x the efficiency and ~1/1000th the cost of conventional methods, the DeltaStem foundation model for cell differentiation, and an active-learning loop that prioritizes its own experiments. The platform has scaled from 27,000 to over one million unique signal combinations, using human stem cells across thousands of developmental contexts rather than cancer cell lines, to preserve physiological relevance.

The company's go-to-market is a hybrid platform-plus-therapeutics model. On the platform side, it offers co-development, licensing, and platform access to pharmaceutical partners seeking to compress cell therapy development timelines; Novo Nordisk is the first disclosed strategic partner following its May 2026 sale of the STEM-PD Parkinson's program to Cellular Intelligence alongside an equity investment. On the therapeutics side, the company acquired and now controls STEM-PD — a Phase 2-ready, FDA Fast Track-designated allogeneic pluripotent stem cell-derived dopaminergic progenitor therapy for Parkinson's disease originating from University of Cambridge and Lund University research — with pipeline expansion signaled into type 1 diabetes (beta cells), orthopedics (cartilage), and Duchenne muscular dystrophy (satellite cells). Revenue is expected to flow through platform licensing/royalties and clinical milestones/royalties from co-developed programs, though the company remains pre-commercial with no approved products. Operations are anchored in Boston with a translational laboratory in Copenhagen, an 11–50 person team, and cumulative funding of over $62M from Khosla Ventures, the Chan Zuckerberg Initiative, AMD Ventures, SciFi VC, Fusion Fund, Novo Nordisk, and others.

Name

Cellular Intelligence

Legal name

Somite Therapeutics, Inc.

Website

https://cellularintelligence.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

Cellular Intelligence is a Boston-based AI-native TechBio company building a universal virtual cell-signaling foundation model and a proprietary capsule-based data platform to rationally design cell differentiation protocols, with a Phase 2-ready Parkinson's cell therapy (STEM-PD) and pipeline expansion into diabetes, orthopedics, and muscular dystrophy.

Ownership category

akta.pro rank

Product category

AI Drug Discovery Platform

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

Stem Cell–Based Regenerative Therapies (HLAAAGAA), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

Keywords

• AI foundation models
• Cell therapy platform
• Regenerative medicine AI
• Computational biology tools
• Drug discovery platform

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Platform Licensing and Co-development: Revenue expected through licensing the AI platform to pharmaceutical partners for cell therapy development and manufacturing optimization. The company applies its AI-native platform to accelerate programs, with clinical and manufacturing data generated further training the foundation model for broader applications.
2. Milestone and Royalty Payments from STEM-PD: Novo Nordisk will receive milestone payments and royalties if the STEM-PD program succeeds. This represents a potential future revenue stream through successful clinical development and commercialization of acquired or co-developed cell therapy programs.
3. Therapeutic Development: Development and commercialization of proprietary cell therapy programs including STEM-PD for Parkinson's disease and future pipeline candidates in type 1 diabetes, orthopedics, and muscular diseases.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Cellular Intelligence develops AI-driven foundation models and platforms to predict and control cell behavior for regenerative medicine. Its core offerings include the Universal Virtual Cell-Signaling Model and DeltaStem foundation models, supported by a proprietary capsule-based data generation platform that produces perturbation data at approximately 1,000x the efficiency of traditional methods. The company applies this platform to advance proprietary cell therapy programs, including the Phase 2-ready STEM-PD therapy for Parkinson's disease acquired from Novo Nordisk, while offering platform access, co-development, and licensing arrangements to pharmaceutical partners.

Product overview

Cellular Intelligence is an AI-native TechBio company operating under the legal entity Somite Therapeutics, building the first universal virtual cell-signaling model to decode and control cellular behavior. The core technology stack comprises the proprietary Capsule-Based Platform for high-throughput data generation (1,000x more efficient than existing methods), the DeltaStem foundation model for predicting cell differentiation, and the Universal Virtual Cell-Signaling Model as the overarching AI engine. The company is applying this platform to advance STEM-PD, a clinical-stage allogeneic cell therapy for Parkinson's disease acquired from Novo Nordisk in May 2026. The platform enables rational protocol design for regenerative medicine by replacing empirical trial-and-error with in silico prediction.

Differentiator

Problem solved

Functional benefit

Products and services

• DeltaStem A foundation model designed to produce any cell type for any person by learning the combinatorial signaling logic that determines cellular behavior. The model accelerates discovery of new cell differentiation protocols and optimizes them for purity, functionality, and scalability. It is intended for pharmaceutical partners and internal therapeutic programs.
• STEM-PD Allogeneic pluripotent stem cell-derived dopaminergic progenitor therapy for Parkinson's disease, designed to replace the dopaminergic neurons lost to the disease rather than only manage symptoms. Phase 2-ready with FDA Fast Track Designation and IND clearance, intended for patients with Parkinson's disease.
• Capsule-Based Platform Proprietary data generation platform using split-and-pool capsule technology with unique barcoding methodology, enabling interrogation of exponentially expanding sets of signaling factor combinations and cell states. Generates massive, context-rich datasets at approximately 1,000x the efficiency of existing methods, covering millions of unique perturbation conditions per experiment. Intended for pharmaceutical partners and internal therapeutic programs.
• Universal Virtual Cell-Signaling Model Foundation model that predicts how any cell in any state changes in response to external signals, acting as a computational twin of living cells. Decodes the grammar of cellular signaling and transforms biology from empirical trial-and-error into predictive engineering, enabling rational protocol design for regenerative medicine and context-specific drug effect prediction. Built on transformer architectures with Neural ODEs for continuous-time dynamics.

Quantifiable outcome

• 1,000x higher efficiency in data generation compared to conventional methods
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• Novo NordiskcoreStrategic or Co-development Partner · 11 May 2026Cellular Intelligence acquired global rights to Novo Nordisk's STEM-PD clinical-stage cell therapy program for Parkinson's disease. Novo Nordisk made a strategic equity investment in Cellular Intelligence and will receive future milestone payments and royalties if the program succeeds. This deal catapults CI into a Phase 2-ready clinical company.
• University of CambridgecoreStrategic or Co-development PartnerSTEM-PD began as a research collaboration between University of Cambridge and Lund University, two of the world's leading centers for Parkinson's research. The academic clinical trial was funded by Novo Nordisk and is the foundation of the current program.
• Lund UniversitycoreStrategic or Co-development PartnerSTEM-PD originated from research collaboration between Lund University and University of Cambridge. Lund's foundational work in Parkinson's research contributed to the development of the allogeneic pluripotent stem cell-derived dopaminergic progenitor therapy.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Market position

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/CellularIntelHQ
• LinkedInlinkedin.com/company/cellular-intelligence

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds4 records

Investors21 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cellular Intelligence